RT Journal Article
SR Electronic
T1 Preexisting Comorbidities Predicting Severe Covid-19 in Older Adults in the UK Biobank Community Cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.06.20092700
DO 10.1101/2020.05.06.20092700
A1 Atkins, Janice L
A1 Masoli, Jane AH
A1 Delgado, Joao
A1 Pilling, Luke C
A1 Kuo, Chia-Ling
A1 Kuchel, George A
A1 Melzer, David
YR 2020
UL http://medrxiv.org/content/early/2020/05/08/2020.05.06.20092700.abstract
AB Background Older COVID-19 hospitalized patients frequently have hypertension, diabetes or coronary heart disease (CHD), but whether these are more common than in the population is unclear. During the initial epidemic in England, virus testing for older adults was restricted to symptomatic hospitalized patients. We aimed to estimate associations between pre-existing diagnoses and COVID-19 status, in a large community cohort.Methods UK Biobank (England) participants assessed 2006 to 2010, followed in hospital discharge records to 2017. Demographic and pre-existing common diagnoses association tested with COVID-19 status (16th March to 14th April 2020) in logistic models, adjusted for demographics, study site and other diagnoses.Results There were 274,356 participants aged 65+, including 448 (0.16%) hospitalized COVID-19 patients. Common co-morbidities in patients were hypertension (58.5%), coronary heart disease (CHD, 21.1%), history of fall or fragility fractures (30.6%), and type 2 diabetes (19.6%). However, in adjusted models, COVID-19 patients were more likely than other participants to have pre-existing dementia (OR=3.07 95% CI 1.71 to 5.50), COPD (OR= 1.82 CI 1.33 to 2.49), depression (OR=1.81 CI 1.36 to 2.40), type 2 diabetes (OR=1.70 CI 1.30 to 2.21), chronic kidney disease and atrial fibrillation. Hypertension was modestly associated (OR=1.29 CI 1.04 to 1.59), but CHD (OR=0.92 CI 0.71 to 1.20) prevalence was similar in COVID-19 patients and other participants.Conclusion Specific co-morbidities are disproportionally common in older adults who develop severe COVID-19. Tailored interventions may be needed, as these results do not support simple age-based targeting to prevent severe COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUK Medical Research Council award MR/S009892/1 (PI Melzer) supports JLA. DM and LCP are supported by the University of Exeter Medical School, and in part by the University of Connecticut School of Medicine. JAHM is supported by NIHR Doctoral Research Fellowship DRF-2014-07-177. Input from CLK was supported by the University of Connecticut. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on application to the UK Biobank (www.ukbiobank.ac.uk/register-apply).